Lamolep - Instructions For Use, Reviews, Price, Analogs Of Tablets

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Lamolep

Lamolep: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Drug interactions
14. 14. Analogs
15. 15. Terms and conditions of storage
16. 16. Terms of dispensing from pharmacies
17. 17. Reviews
18. 18. Price in pharmacies

Latin name: Lamolep

ATX code: N03AX09

Active ingredient: lamotrigine (Lamotrigine)

Manufacturer: Gedeon Richter (Hungary)

Description and photo updated: 30.11.2018

Prices in pharmacies: from 390 rubles.

Buy

Lamolep is an anticonvulsant drug.

Release form and composition

Dosage form - tablets: almost white or white, round biconvex, engraved on one side "L25", "L50" or "L100", depending on the dosage (in a cardboard box 3 blisters of 10 tablets and instructions for use of Lamolep).

Composition of 1 tablet:

• active substance: lamotrigine - 25, 50 or 100 mg;
• excipients (25/50/100 mg, respectively): anhydrous colloidal silicon dioxide - 0.1 / 0.2 / 0.4 mg; magnesium stearate - 0.4 / 0.8 / 1.6 mg; sodium carboxymethyl starch (type A) - 3/6/12 mg; povidone - 2.5 / 5/10 mg; lactose monohydrate - 16.25 / 32.5 / 65 mg; microcrystalline cellulose - 32.75 / 65.5 / 131 mg.

Pharmacological properties

Pharmacodynamics

The action of lamotrigine, the active substance of Lamolep, is aimed at stabilizing the cell membrane (by influencing the voltage-gated sodium channels) and blocking the release of neurotransmitters, mainly glutamate. Glutamate is an activating amino acid and plays a key role in the occurrence of epileptic seizures.

In two clinical trials, lamotrigine has been shown to be effective in preventing mood disorders in bipolar patients. It was found that due to therapy, the duration of the remission period in bipolar disorders increases, since Lamolep has a more pronounced effect on depression.

Pharmacokinetics

Lamotrigine after oral administration from the intestine is absorbed quickly and completely, without significantly undergoing the effect of the first passage through the liver. Time to reach C _max (maximum concentration) - 2.5 hours. When Lamolep is taken with food, absorption slows down somewhat, but food does not affect the degree of absorption.

After a single dose of up to 450 mg, the pharmacokinetic parameters of lamotrigine are linear. The C _max value in the equilibrium state has individual variation.

Lamotrigine binds to blood plasma proteins at a level of 55%. The likelihood that a toxic effect may develop when a substance is displaced from its bond with proteins is small. V _d (volume of distribution) - 0.92-1.22 l / kg.

The metabolic process of lamotrigine occurs in the liver to glucuronides (N-glucuronides make up 65% of the metabolites of the substance) due to the enzyme uridine diphosphate glucuronyl transferase (UDP-glucuronyl transferase). To a moderate extent, lamotrigine induces its own metabolism, the extent of which depends on the dose taken. There is no information on the effect of the substance on the pharmacokinetic processes of other drugs with antiepileptic action. The development of drug interactions between lamotrigine and drugs whose metabolism is associated with CYP ₄₅₀ is hardly possible.

In healthy adults, clearance of lamotrigine at steady state averages 39 ± 14 ml / min. Excretion is carried out by the kidneys in the form of metabolites (glucuronides). Up to 10% of the substance is excreted unchanged by the kidneys, about 2% through the intestines. Clearance and T _1/2 (half-life) do not depend on the dose. In healthy adults, T _1/2 is in the 24–35 hour range.

The mean clearance of lamotrigine in Gilbert's syndrome is 32% lower than in the control group of patients, but these indicators do not differ from those observed in the general population.

When used in combination with other drugs, T _{1/2 of} lamotrigine changes significantly. The value of this indicator decreases to 14 hours against the background of combination therapy with inducers of enzymes of microsomal oxidation in the liver (carbamazepine or phenytoin), with simultaneous use with valproic acid T _1/2 increases up to 70 hours.

The clearance in children per kg of body weight is higher than in adults. The T _1/2 value is usually less than in the adult population, when combined with inducers of microsomal oxidation enzymes in the liver, it is 7 hours, with valproic acid - from 45 to 50 hours.

The initial dose for patients with renal impairment is calculated based on the standard dosage regimen for antiepileptic drugs. With a significant decrease in renal function, a dose reduction may be required.

Features of the dosage regimen for the initial, increasing and maintenance doses in hepatic insufficiency: with an average degree, a dose reduction of 50% is required; in severe cases, the dose is reduced by 75%.

The possibility of increasing the dose and the selection of the maintenance dose are based on the clinical effect.

Indications for use

• epilepsy: prescribed to patients over 12 years old for the treatment of generalized and partial seizures (including tonic-clonic seizures and seizures in Lennox-Gastaut syndrome) as monotherapy or in combination with other antiepileptic drugs;
• bipolar disorders: prescribed for patients over 18 years of age to prevent mood disorders (mainly episodes of depression).

Contraindications

Absolute:

• severe hepatic dysfunction;
• lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
• under 12 years of age (treatment of epilepsy) or 18 years of age (treatment of bipolar disorder);
• individual intolerance to the components of the drug.

Relative (Lamolep tablets are prescribed under medical supervision):

• renal failure (associated with the likelihood of cumulation of the glucuronide metabolite);
• pregnancy and lactation.

Lamolep, instructions for use: method and dosage

Lamolep tablets are taken without chewing, inside and washed down with a small amount of water.

If a single dose includes an incomplete tablet, for children with epilepsy and patients with hepatic impairment, it should be adjusted to contain only the whole number of tablets.

Epilepsy

Monotherapy

Recommended dosage regimen of Lamolep:

• 1-14th day: 25 mg once a day;
• 15-28th day: 50 mg once a day;
• further use: until the optimal effect is achieved, the dose can be increased by 50-100 mg every 1–2 weeks; maintenance daily dose is usually 100-200 mg in 1 or 2 doses, in some cases 500 mg per day is prescribed.

Combination therapy

Dosage regimen for the combined therapy of Lamolep with valproic acid with / without another antiepileptic drug:

• 1-14th day: 25 mg every other day;
• 15-28th day: 25 mg once a day;
• further use: until the optimal effect is achieved, the dose can be increased by 25-50 mg every 1–2 weeks; maintenance daily dose is usually 100-200 mg in 1 or 2 divided doses.

Dosage regimen for the combined use of Lamolep with an inducer of microsomal oxidation enzymes in the liver with / without another antiepileptic drug (carbamazepine, phenytoin, primidone, phenobarbital, but not valproic acid):

• 1-14th day: 50 mg once a day;
• 15-28th day: 100 mg per day in 2 divided doses;
• further use: until the optimal effect is achieved, the dose can be increased by 100 mg every 1–2 weeks; maintenance daily dose is usually 200-400 mg in 2 divided doses, in some episodes 700 mg per day is prescribed.

In cases where combination therapy is carried out with an antiepileptic agent, the pharmacokinetic interactions of which with lamotrigine are not known, the dose of Lamolep should be increased in smaller doses (the scheme described for valproic acid).

General recommendations

If the rate of dose increase is observed, the likelihood of a skin rash is reduced.

At the initial stage of combined treatment or when it is canceled, the effect of drugs on the pharmacokinetic parameters of lamotrigine should be taken into account, if necessary, the dose is adjusted.

It is required to take into account that with a sharp cancellation of Lamolep, seizures may develop. If it is necessary to cancel therapy on the basis of safety requirements (for example, with the development of a rash), the dose is gradually reduced over two weeks.

Bipolar Disorders

In bipolar disorders, Lamolep is indicated for the prevention of episodes of depression.

In order to prevent depression, the following dosage regimen must be followed. With short-term treatment, the dose of Lamolep is increased gradually, over 6 weeks, until a stabilizing maintenance dose is reached, then, with an appropriate clinical picture of the disease, the intake of a psychotropic and / or other antiepileptic drug can be discontinued.

The efficacy of Lamolep in the case of mania / manic conditions is controversial, therefore adjuvant therapy may be required to prevent episodes of mania.

Combination therapy of Lamolep with inhibitors of enzymes of microsomal oxidation in the liver (for example, simultaneous use with valproic acid):

• 1-2 weeks: 25 mg every other day;
• 3-4 weeks: 25 mg 1 time per day;
• 5th week: 50 mg per day for 1-2 doses;
• maintenance dose: 100 mg per day for 1-2 doses, maximum - 200 mg per day.

Combination therapy of Lamolep with inducers of microsomal oxidation enzymes in the liver (for example, simultaneous use with phenobarbital and carbamazepine, but without valproic acid):

• 1-2 weeks: 50 mg once a day;
• 3-4 weeks: 100 mg per day, divided into 2 doses;
• 5th week: 200 mg, divided into 2 doses;
• 6th week: 300 mg, divided into 2 doses;
• 7th week and beyond: 400 mg, divided into 2 doses.

Combination therapy of Lamolep with drugs, the pharmacological interaction of which with lamotrigine is either not known or possible, (for example, with bupropion, lithium):

• 1-2 weeks: 25 mg once a day;
• 3-4 weeks: 50 mg per day for 1-2 doses;
• 5th week: 100 mg per day for 1-2 doses;
• maintenance dose: 200 mg per day for 1-2 doses, during clinical trials, daily doses of 100 to 400 mg were used.

After an effective maintenance stabilizing dose of Lamolep is reached (maximum 400 mg per day), psychotropic drugs can be canceled.

During the first week after the end of therapy with inhibitors of enzymes of microsomal oxidation in the liver (for example, valproic acid), the stabilizing dose should be increased by 2 times, but not more than 100 mg per week. Thus, during the first 7 days, the daily dose should be 200 mg in 2 divided doses. In the future, she is appointed as a supporting one.

After the inducer of microsomal oxidation enzymes in the liver (for example, carbamazepine) is canceled, the dose of Lamolep is gradually reduced over three weeks according to one of three schemes (1st week / 2nd week / further therapy):

1. 400 mg / 300 mg / 200 mg.
2. 300 mg / 225 mg / 150 mg.
3. 200 mg / 150 mg / 100 mg.

If psychotropic / antiepileptic drugs that most likely do not have a pharmacokinetic effect on Lamelep (for example, bupropion, lithium) are canceled, then an increased dose should be used as a maintenance dose (200 mg in 2 divided doses), the recommended daily dose is in the range from 100 to 400 mg.

After the withdrawal of drugs that do not interact with lamotrigine, the dose of lamolep is increased according to the scheme described for valproic acid.

There is no clinical experience in titrating doses of lamotrigine after additional prescribing of drugs, in this regard, the use of the following doses is recommended, established on the basis of the results of studies of drug interactions.

When prescribing inhibitors of enzymes of microsomal oxidation in the liver (for example, valproic acid), the degree of dose adjustment is determined by the initial daily dose of Lamolep:

• 400 mg: 200 mg
• 300 mg: 150 mg:
• 200 mg: 100 mg.

If an inducer of microsomal oxidation enzymes in the liver is additionally prescribed (for example, simultaneous use with carbamazepine), the degree of correction depends on the initial daily dose of Lamolep without valproic acid (1st week / 2nd week / further therapy):

• 200 mg: 200 mg / 300 mg / 400 mg;
• 150 mg: 150 mg / 225 mg / 300 mg;
• 100 mg: 100 mg / 150 mg / 200 mg.

When prescribing psychotropic / antiepileptic drugs with an unknown pharmacokinetic interaction with Lamolep (for example, with lithium, bupropion), the dose that was achieved with an increase in the dose - 200 mg per day (in the range from 100 to 400 mg) is used.

In cases of the appointment of antiepileptic drugs with an unknown pharmacokinetic interaction, when adjusting the dose, you should focus on the recommendations regarding the use of valproic acid.

When Lamolep is canceled, a gradual dose reduction is required.

Application of Lamolep in special patient groups

The recommended dosage regimen of Lamolep for patients with hepatic impairment:

• medium degree (on the Child-Pugh scale, class B): the initial / maintenance dose, as well as the dose increase, should be reduced by 50%;
• severe degree (on the Child-Pugh scale, class C): the initial / maintenance dose, as well as the dose increase, should be reduced by 75%.

Dose escalation / maintenance doses are determined by the clinical effect.

For patients with renal insufficiency, Lamolep is prescribed with caution. The initial dose of the drug in the terminal stage of renal failure is established in accordance with the standard prescription regimen; with a pronounced decrease in renal function, the maintenance dose can be reduced.

Side effects

Classification of possible adverse reactions (> 10% - very often;> 1% and 0.1% and 0.01% and <0.1% - rarely; <0.01% - very rare).

Adverse reactions recorded when using Lamolep for the treatment of epilepsy:

• the digestive system during monotherapy (the results were obtained in the course of clinical studies): often - vomiting, nausea, diarrhea;
• the digestive system during combination therapy: very often - vomiting, nausea; often - diarrhea; very rarely - abnormal liver function, increased activity of liver enzymes, liver failure (usually liver disorders are part of the hypersensitivity syndrome, but they are not always accompanied by other symptoms of hypersensitivity);
• the nervous system during monotherapy (the results were obtained in the course of clinical trials): very often - headache; often - insomnia, drowsiness, tremors, dizziness; infrequently - ataxia; rarely - nystagmus;
• nervous system during combination therapy: very often - ataxia, dizziness, headache, drowsiness; often - nystagmus, insomnia, tremor; very rarely - worsening of Parkinson's disease, movement disorders, agitation, aseptic meningitis, loss of balance, increased frequency of seizures, extrapyramidal symptoms, choreoathetosis; there is information about the worsening of extrapyramidal symptoms of parkinsonism in patients with concomitant Parkinson's disease, isolated cases describe the appearance of extrapyramidal symptoms and choreoathetosis in patients who did not have previous disorders;
• skin during monotherapy (the results were obtained during clinical trials): very often - skin rash (often - maculopapular rash, occurs in the first 8 weeks of treatment, disappears after Lamolep is discontinued);
• skin during combination therapy: very often - skin rash; rarely - Stevens-Johnson syndrome; very rarely - Lyell's syndrome (toxic epidermal necrolysis), in some cases, after recovery, scarring occurs;
• sense organs during monotherapy: infrequently - blurred vision, diplopia;
• sense organs during combination therapy: very often - decreased visual acuity, diplopia; rarely - conjunctivitis;
• hematopoietic system: very rarely - pancytopenia, leukopenia, neutropenia, anemia, thrombocytopenia, aplastic anemia, lymphadenopathy, agranulocytosis (there may be a connection with hypersensitivity);
• immune system: skin rash (part of the hypersensitivity syndrome, which can occur with varying degrees of severity); very rarely - hypersensitivity syndrome, including fever, lymphadenopathy, liver and blood disorders, facial swelling, disseminated intravascular coagulation syndrome, multiple organ failure (it should be borne in mind that the development of early signs of hypersensitivity, such as lymphadenopathy and fever, is possible even against the background of the absence of obvious signs of a rash; in case of such violations, you need to consult a doctor, if other reasons for the appearance of these reactions are not identified, Lamolep is canceled);
• endocrine system: rarely - hypothyroidism, struma (goiter);
• cardiovascular system: infrequently - vasodilation, orthostatic hypotension, palpitations, hot flashes, hypertension, tachycardia, syncope (fainting);
• musculoskeletal system: very rarely - lupus-like reactions;
• psyche: often - aggressiveness, irritability; very rarely - hallucinations, tics, confusion;
• others: often - increased fatigue (is dose-dependent).

Adverse reactions recorded when using Lamolep for the treatment of bipolar disorders:

• nervous system: very often - headache; often - drowsiness, agitation, dizziness;
• skin: very often - skin rash; rarely - Stevens-Johnson syndrome;
• digestive system: often - xerostomia;
• musculoskeletal system: often - arthralgia;
• others: back pain, myalgia (dose-dependent).

When assessing the side effects of Lamolep, both groups should be taken into account. the listed adverse reactions.

Overdose

There is evidence of a single dose of Lamolep in a dose that is 10–20 times higher than the maximum therapeutic dose.

The main symptoms of lamotrigine overdose are ataxia, nystagmus, drowsiness, vomiting, headache, impaired consciousness, dizziness, coma.

The therapy is carried out in a hospital setting, it consists of symptomatic and supportive treatment based on the clinical picture or the recommendations of the national poison control center.

special instructions

At the beginning of the course for eight weeks, side effects of lamotrigine, such as skin reactions, may develop. As a rule, skin rashes appear mild and disappear spontaneously. However, severe forms are also possible, for example, Stevens-Johnson syndrome and Lyell's syndrome, in which hospitalization and Lamolep's cancellation are required.

The frequency of severe forms of skin reactions among adult patients with epilepsy was 1 ÷ 500, among them Stevens-Johnson syndrome was observed in half of the cases.

Children are more prone to the development of severe forms of skin reactions. According to numerous clinical observations, the number of cases of skin reactions in which hospitalization of children was required was 1 ÷ 300-1 ÷ 100.

An early rash in children can be easily confused with a rash that occurs against a background of infectious diseases, therefore, in cases where a rash appears in combination with a high temperature in the first 8 weeks of treatment, it is necessary to assume the development of a drug reaction.

There is an assumption that in adults the overall risk of skin reactions is closely associated with high initial doses and non-compliance with the dose escalation regimen, as well as with combination therapy with valproic acid.

When prescribing Lamolep to patients with a history of allergic reactions or rash in response to taking other antiepileptic drugs, care must be taken. Since the incidence of rash development (which was not classified as serious) during treatment in this group of patients was observed 3 times more often than in patients without these disorders in the history.

In the event of a rash, the condition of each patient, regardless of age, should be immediately and thoroughly examined. Lamolep is canceled, with the exception of patients in whom it has been reliably established that there is no connection between the appearance of a rash and taking the drug.

The rash can occur in combination with various systemic manifestations of hypersensitivity, including fever, facial edema, lymphadenopathy, and reactions from the hematopoietic system and liver. Violations can manifest themselves with varying degrees of severity, sometimes disseminated intravascular coagulation with multiple organ failure can develop. It should be borne in mind that early signs of hypersensitivity (eg, lymphadenopathy, high fever), skin rashes are not always accompanied. If the appearance of these reactions cannot be explained by another reason, Lamolep is immediately canceled.

The combined preparation containing 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel increases the plasma clearance of lamotrigine by about 2 times. If, against the background of Lamolepom therapy, a woman starts / ends the use of hormonal contraceptives, a dose adjustment of lamotrigine may be required.

With long-term use of Lamolep, a change in the metabolism of folic acid is possible, since lamotrigine is one of the weak inhibitors of the enzyme DHFR (dihydrofolate reductase). At the same time, prolonged use of the drug has no effect on the average volume of erythrocytes, hemoglobin, the concentration of folic acid in erythrocytes and plasma.

Hepatic dysfunction in most cases is part of the hypersensitivity syndrome (it can occur on its own, without the appearance of other signs).

When treating patients on hemodialysis with renal failure, it is necessary to take into account that an average of 20% of lamotrigine is excreted from the body during a four-hour hemodialysis.

Without consulting a doctor, lamolep should not be prescribed to patients who are already receiving any other medicinal products that include lamotrigine.

The effectiveness of epilepsy therapy is assessed by a decrease in the frequency of spikes on the EEG (electroencephalogram) by 78–98%.

The abrupt cessation of the use of Lamolep, like other antiepileptic drugs, provokes the development of epileptic seizures (ricochet syndrome). Cancellation of epilepsy therapy should be carried out gradually, gradually reducing the dose over two weeks, except in cases where immediate withdrawal of the drug is necessary (for example, when a skin rash appears).

There is evidence that severe convulsive seizures, including status epilepticus, can cause the development of rhabdomyolysis, dysfunction of many organs, as well as disseminated intravascular coagulation syndrome (DIC), possibly fatal. Such cases have been described in connection with the use of drugs containing lamotrigine.

Patients with epilepsy may have symptoms of depression and / or bipolar disorder. Patients with epilepsy and comorbid bipolar disorders are at high risk of suicide, therefore, patients with an increased tendency to commit suicide should be treated under close supervision of their condition.

Influence on the ability to drive vehicles and complex mechanisms

At the beginning of therapy with Lamolep, it is prohibited to drive vehicles. In the future, the degree and duration of the restriction is determined individually by the doctor.

Application during pregnancy and lactation

Lamolep during pregnancy and breastfeeding can be prescribed only in cases where the expected benefit is higher than the potential risk.

There is insufficient clinical evidence of the safety / efficacy of lamotrigine during pregnancy. There is evidence of an increase in the likelihood of fetal congenital anomalies of the oral cavity. Physiological changes observed during pregnancy can affect the concentration of the active substance and / or its therapeutic effect. A decrease in the concentration of lamotrigine in pregnant women has been reported. The appointment of Lamolep should be ensured by the appropriate patient management tactics.

Lamotrigine passes into breast milk to varying degrees, and its level in infants can reach a concentration corresponding to approximately 50% of that registered in the mother. The serum content of the drug in some breastfed infants can reach levels at which pharmacological effects are manifested.

Studies on the effect of Lamolep on human fertility have not been conducted.

Pediatric use

Contraindication:

• children under 12 years of age: epilepsy;
• children and adolescents under 18 years of age: bipolar disorders.

With impaired renal function

For patients with renal insufficiency, Lamolep is prescribed with caution.

For violations of liver function

It is contraindicated to use Lamolep for severe violations of the hepatic function.

Drug interactions

The main enzyme metabolizing lamotrigine is UDP-glucuronyl transferase. There is no evidence to support the ability of lamotrigine to induce clinically significant induction or inhibition of liver microsomal enzymes. Therefore, an interaction between lamotrigine and drugs that are metabolized by cytochrome P ₄₅₀ isoenzymes is unlikely. The substance is able to induce its own metabolism, but this effect is moderate in intensity without clinically significant consequences.

Valproic acid is one of the potent inhibitors of lamotrigine glucuronidation. Against the background of suppression of glucuronidation of a substance, its metabolic rate decreases and the average T _{1/2 is} approximately 2 times longer.

Some of the antiepileptic drugs, including carbamazepine, phenytoin, primidone, phenobarbital, induce microsomal liver enzymes, which accelerates the glucuronidation of lamotrigine and, as a result, the process of its metabolism. Possible interactions of Lamolep with these drugs:

• carbamazepine: there is information about the development of disorders from the central nervous system, including ataxia, dizziness, diplopia, blurred vision and nausea in patients; when the dose of carbamazepine is reduced, these symptoms disappear;
• phenobarbital: the concentration of lamotrigine is reduced by 40%;
• rifampicin: lamotrigine clearance increases, T _1/2 decreases (associated with the induction of liver microsomal enzymes, which are responsible for glucuronidation); when carrying out combined therapy, the dosage regimen of lamotrigine should correspond to the scheme that is recommended when taken together with agents that induce microsomal oxidation enzymes in the liver;
• ritonavir / lopinavir: the plasma concentration of lamotrigine decreases by about 2 times (possibly associated with the induction of glucuronidation); when conducting combined therapy, the dosage regimen of lamotrigine should correspond to the scheme that is recommended when used together with agents that induce microsomal oxidation enzymes in the liver;
• ritonavir / atazanavir: studies have shown that combination therapy leads to a decrease in AUC (area under the concentration-time curve) and _{Cmax of} lamotrigine;
• combined oral contraceptives: there is a clinically significant increase in clearance and a decrease in AUC and _{Cmax of} lamotrigine.

Drugs that have a slight effect on the glucuronidation of lamotrigine: bupropion, lithium preparations, olanzapine, felbamate, levetiracetam, oxcarbazepine, gabapentin, topiramate, pregabalin, zonisamide.

According to the studies, lamotrigine does not affect the plasma concentration of other antiepileptic drugs taken in combination with it, does not displace them from the bonds with plasma proteins. It can also be assumed that risperidone, clozapine, phenelzine, trazodone, and sertraline have no effect on the clearance of lamotrigine.

The inhibition of lamotrigine by fluoxetine, bupropion, amitriptyline, clonazepam, lorazepam and haloperidol has minimal effect on the formation of the primary metabolite of lamotrigine 2-N-glucuronide.

Analogs

Analogs of Lamolep are Lamitor DT, Konvulsan, Lameptil, Vero-Lamotrigin, Lamictal, Lamitor, Lamotrigine, Seizar, Lamotrix, etc.

Terms and conditions of storage

Store at temperatures up to 30 ° C. Keep out of the reach of children.

The shelf life is 5 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Lamolep

Reviews of Lamolep characterize it as an effective drug. Side effects are rare. Many patients note that, subject to the requirement of a gradual increase in the dose, the likelihood of developing negative consequences is minimal.

The price of Lamolep in pharmacies

Approximate price for Lamolep for 30 tablets per pack:

• dosage 25 mg - 385-435 rubles;
• dosage 50 mg - 708-790 rubles;
• dosage 100 mg - 1234-1419 rubles.

Lamolep: prices in online pharmacies

Drug name Price Pharmacy

Lamolep 25 mg tablets 30 pcs. 390 RUB Buy

Lamolep tablets 25mg 30 pcs. 438 r Buy

Lamolep 50 mg tablets 30 pcs. 461 r Buy

Lamolep tablets 50mg 30 pcs. 794 r Buy

Lamolep 100 mg tablets 30 pcs. 1249 RUB Buy

Lamolep tablets 100mg 30 pcs. 1442 RUB Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!